Brokerages Expect Supernus Pharmaceuticals (SUPN) to Post $0.46 Earnings Per Share

Wall Street brokerages forecast that Supernus Pharmaceuticals (NASDAQ:SUPN) will announce $0.46 earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have made estimates for Supernus Pharmaceuticals’ earnings, with estimates ranging from $0.42 to $0.50. Supernus Pharmaceuticals posted earnings of $0.32 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 43.8%. The firm is scheduled to announce its next earnings report on Wednesday, August 1st.

On average, analysts expect that Supernus Pharmaceuticals will report full year earnings of $1.91 per share for the current financial year, with EPS estimates ranging from $1.85 to $2.00. For the next financial year, analysts expect that the business will report earnings of $2.65 per share, with EPS estimates ranging from $2.22 to $3.05. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.18. The firm had revenue of $88.44 million during the quarter, compared to analyst estimates of $87.84 million. Supernus Pharmaceuticals had a return on equity of 30.18% and a net margin of 21.89%.

Several research firms recently commented on SUPN. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 16th. ValuEngine upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Zacks Investment Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 5th. Finally, Berenberg Bank assumed coverage on Supernus Pharmaceuticals in a research note on Thursday, February 1st. They issued a “buy” rating and a $66.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $51.36.

Supernus Pharmaceuticals stock traded up $0.40 during trading on Friday, hitting $54.95. The company’s stock had a trading volume of 37,149 shares, compared to its average volume of 908,313. The firm has a market capitalization of $2.85 billion, a P/E ratio of 43.61 and a beta of 1.14. Supernus Pharmaceuticals has a 1-year low of $33.30 and a 1-year high of $59.05. The company has a current ratio of 4.90, a quick ratio of 4.74 and a debt-to-equity ratio of 0.90.

In other news, VP Victor Vaughn sold 60,000 shares of the company’s stock in a transaction dated Thursday, April 5th. The stock was sold at an average price of $45.33, for a total value of $2,719,800.00. Following the completion of the sale, the vice president now owns 24,344 shares of the company’s stock, valued at $1,103,513.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 67,132 shares of the company’s stock in a transaction dated Friday, May 11th. The stock was sold at an average price of $53.11, for a total value of $3,565,380.52. Following the completion of the sale, the vice president now directly owns 32,500 shares of the company’s stock, valued at approximately $1,726,075. The disclosure for this sale can be found here. Insiders have sold 152,850 shares of company stock valued at $7,596,524 over the last 90 days. 6.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of SUPN. California Public Employees Retirement System boosted its position in shares of Supernus Pharmaceuticals by 21.1% in the third quarter. California Public Employees Retirement System now owns 47,090 shares of the specialty pharmaceutical company’s stock worth $1,884,000 after buying an additional 8,190 shares during the period. Louisiana State Employees Retirement System boosted its position in shares of Supernus Pharmaceuticals by 7.8% in the fourth quarter. Louisiana State Employees Retirement System now owns 22,100 shares of the specialty pharmaceutical company’s stock worth $881,000 after buying an additional 1,600 shares during the period. Convergence Investment Partners LLC boosted its position in shares of Supernus Pharmaceuticals by 5.1% in the fourth quarter. Convergence Investment Partners LLC now owns 49,345 shares of the specialty pharmaceutical company’s stock worth $1,966,000 after buying an additional 2,385 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Supernus Pharmaceuticals by 20.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 286,003 shares of the specialty pharmaceutical company’s stock worth $11,398,000 after buying an additional 48,732 shares during the period. Finally, Acadian Asset Management LLC boosted its position in shares of Supernus Pharmaceuticals by 2.0% in the fourth quarter. Acadian Asset Management LLC now owns 1,280,179 shares of the specialty pharmaceutical company’s stock worth $51,013,000 after buying an additional 24,491 shares during the period. 97.29% of the stock is owned by institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply